Determining eligibility for anti‐amyloid treatments using blood biomarkers

In 21 patients who underwent a second test with CSF or PET, all 15 patients who were positive by PrecivityAD2 were also positive by CSF or PET. Although this study is very small, these data support providing anti-amyloid treatments based on high accuracy blood biomarker tests to patients with a high clinical likelihood of amyloid pathology.